) into the scrapie-associated protease-resistant isoform (PrP Sc ) of prion protein (PrP) is the central event in transmissible spongiform encephalopathies or prion diseases. Differences in transmissibility and susceptibility are largely determined by polymorphisms in PrP, but the exact molecular mechanism behind PrP conversion and the modulation by disease-associated polymorphisms is still unclear. Consequently, a second step after PrP C -PrP Sc -binding should determine the observed differences in PrP conversion efficiencies. Further study of this second step may provide a future tool to determine the mechanism underlying refolding of PrP C into PrP Sc and supports the use of conversion-resistant polymorphic PrP C variants as a potential therapeutic approach to interfere with PrP conversion in transmissible spongiform encephalopathy development.
INTRODUCTION
Transmissible spongiform encephalopathy (TSE) diseases are fatal neurodegenerative disorders and include (among others) familial, sporadic and variant Creutzfeldt-Jakob disease in humans, bovine spongiform encephalopathy (BSE) in cattle and scrapie in sheep. TSEs (or prion diseases) are characterized by the formation and accumulation of proteaseresistant prion protein (PrP Sc ) mainly in tissues of the central nervous system. Formation of PrP Sc is a post-translational process and involves refolding (conversion) of the hostencoded prion protein (PrP C ) into partially protease-resistant forms (PrP Sc ) (DeArmond & Prusiner, 2003) .
Scrapie in small ruminants (e.g. sheep) is one of the best documented models for natural TSE transmission. Polymorphisms in PrP have been shown to be of importance in both interspecies and intraspecies transmissibilities (Bossers et al., 2003) . Susceptibility of sheep to scrapie seems mainly dictated by polymorphisms in the gene encoding the prion protein itself, and to date over 20 different naturally occurring polymorphisms (only one mutation per allele) of PrP have been described (Goldmann et al., 1990 (Goldmann et al., , 1991 Belt et al., 1996; Bossers et al., 1996; Junghans et al., 1998; Elsen et al., 1999; Thorgeirsdottir et al., 1999; Tranulis et al., 1999; O'Rourke et al., 2000) . The effects of polymorphisms in ovine PrP on the relative susceptibility of sheep to scrapie have been gauged in epidemiological studies of natural scrapie outbreaks, in experimental transmissions to and from sheep, and in cell-free conversion assays (Goldmann et al., 1994; Bossers et al., 1996 Bossers et al., , 1997 Bossers et al., , 1999 Bossers et al., , 2000 Hunter et al., 1996) . Polymorphisms at sheep PrP aa 136, 154 and 171 have been shown to be most relevant in association with differential TSE susceptibility. Several studies have shown that an alanine at position 136, arginine at position 154 and glutamine at position 171 (ARQ) to be the phylogenetic wild-type (wt) PrP, with intermediate susceptibility to scrapie. The polymorphism associated with increased susceptibility to scrapie is the substitution of alanine with valine at codon 136 (VRQ; 136V) and thus far the only polymorphism shown to be associated with decreased susceptibility or even resistance to natural scrapie is the substitution of glutamine with arginine at codon 171 (ARR; 171R). Cell-free conversion of PrP C provides an excellent in vitro model, in which relative amounts of produced proteinase K (PK)-resistant PrP reflect important biological aspects of TSEs at the molecular level (Caughey et al., 1995; Bossers et al., 1997 Bossers et al., , 2000 Bossers et al., , 2003 Raymond et al., 1997 Raymond et al., , 2000 Bossers, 1999) . In sheep scrapie, this technique has shown that 136V and wt-PrP C are readily converted into PKresistant PrP by various types of PrP Sc isolated from sheep having different PrP genotypes. In contrast, 171R-PrP is hardly converted into PK-resistant PrP (Bossers et al., 1997 (Bossers et al., , 2003 Bossers, 1999; Raymond et al., 2000) .
Studies on the conversion of hamster and mouse PrP C isoforms resulted in indications that diminished acquisition of PK resistance is not due to lack of binding of PrP C to PrP Sc (Horiuchi et al., 2000) . However, no data on binding efficiencies of ovine PrP C to PrP Sc are available to date. Furthermore, whereas differences in susceptibility of-and transmissibility in sheep can entirely be explained at the molecular level by the effects of single polymorphisms in PrP C or PrP Sc on PrP conversion, the exact molecular mechanism determining these differences is still unknown Dubois et al., 2002; Tranulis, 2002; Sabuncu et al., 2003) .
In the present study, sheep scrapie susceptibility-linked polymorphisms were used to determine whether differential binding efficiencies of sheep PrP C to PrP Sc determine the observed differential conversion efficiencies of sheep PrP (Bossers et al., 1997 Raymond et al., 1997 Raymond et al., , 2000 .
METHODS
PrP C constructs and expression. The three sheep PrP C variants used (136V, wt and 171R) were cloned, expressed and characterized as described previously (Bossers et al., 1997) . Briefly, PrP open reading frames (ORF) were subcloned into the eukaryotic expression vector pECV7. The vectors containing PrP ORF were stably transfected into Chinese hamster ovary (CHO) cells. High and stable expressing single-cell-clones were selected by immunoperoxidase monolayer assay and Western blotting, using rabbit anti-peptide antiserum R521-7 (van Keulen et al., 1995) .
Radiolabelling and purification of PrP C . Radiolabelling and purification of the three PrP C variants were performed as described previously Bossers et al., 2000) . Briefly, single cell clones expressing the different PrP C variants were starved for 30-60 min in label medium and subsequently labelled with 1 mCi (37 MBq) [ 
Slabelled PrP
C was immunopurified by PrP-specific antiserum R521-7 captured by protein A-Sepharose (10 % w/v), which was eluted in 0?1 M acetic acid.
Radiolabelling and purification of classical swine fever virus (CSFV) glycoprotein E2. For labelling, an expression vector containing the gene encoding glycoprotein E2 of CSFV transfected into SK6 cells (van Gennip et al., 2002) was used. Radiolabelling and purification of E2 were essentially performed as described above, albeit on a larger scale.
35
S-labelled E2 was immunopurified using monoclonal antibody V3 (Wensvoort, 1989) and eluted in 0?1 M acetic acid.
PrP
Sc purification and analysis. PrP Sc was isolated from brain tissue of clinically ill scrapie sheep with either homozygous alleles for 136V-PrP or wt-PrP. PrP genotypes were determined by Sanger sequencing of the full PrP ORF as described previously (Bossers et al., 1996) . PrP Sc was purified by ultracentrifugational pelleting from Sarkosyl-homogenated brains as described previously (Caughey et al., 1995; Bossers et al., 1997) . The final pellets were sonicated in PBS containing 1?0 % zwitter-reagent . Yields of PrP Sc were quantified by SDS-PAGE (12 % NuPAGE; Invitrogen) and Western blotting using antiserum R521-7.
Conversion-binding assay. Conversion and binding efficiencies were determined by double volume cell-free conversion reactions essentially as described previously (Horiuchi et al., 2000; Priola & Lawson, 2001 ) and adapted to ovine cell-free conversion conditions as used before (Caughey et al., 1995; Bossers et al., 1997 Bossers et al., , 2000 . Briefly, PrP
Sc was partially denatured in 2?5 M guanidinium-hydrochloride (GdnHCl) for at least 2?5 h at 37 uC. Aliquots of denatured PrP Sc (2-4 mg per reaction) were mixed with 10 000-20 000 c.p.m. purified 35 S-labelled PrP C (~20-40 ng 35 S-labelled PrP C ) and further diluted to a final concentration of 1?0 M GdnHCl in conversion buffer (50 mM sodium citrate, pH 6?0, 5 mM cetylpyridinium chloride, 1 % N-lauroylsarcosine and protease inhibitors). Reactions were incubated for 3 days at 37 uC (or shorter for the kinetic experiments). After incubation, the reaction volume was split in two equal aliquots in separate siliconized tubes. One aliquot was used for binding analysis and centrifuged for 30 min at 17 500 g at room temperature, the supernatant was transferred to a separate siliconized tube (unbound fraction) and the pellet (bound fraction) dissolved in 1 % SDS by sonication. From the second aliquot, 1/10 volume was transferred to a separate siliconized tube (reference fraction) and the remaining 9/10 volume was treated with 35 mg PK ml 21 for 1 h at 37 uC. PK was inactivated by the addition of Pefabloc-SC (Roche).
All the samples were methanol-precipitated and the pellet was dried and dissolved in Laemmli SDS-PAGE sample buffer containing 5 % (v/v) 2-mercaptoethanol and 4 M urea. Samples were run on SDS-PAGE (12 % NuPAGE; Invitrogen), the dried gels were visualized by phosphorimaging and analysed using a STORM-840 imager and the ImageQuant 5.1 software (Molecular Dynamics). Binding percentages were calculated by dividing the amount of labelled PrP C (molecular mass between 24 and 28?5 kDa) of each fraction [pellet (p) and supernatant (s)] by the total amount of labelled PrP C (p+s). Conversion percentages were calculated by dividing the amount of labelled PrP left after PK digestion (molecular mass between 19 and 21?5 kDa) by the amount of labelled PrP C in the reference fraction (molecular mass between 24 and 28?5 kDa).
Statistical analysis of binding efficiencies. Statistical calculations were performed using the GenStat 6.1 program. To compensate for differences in possible variance as a result of a fixed scale, variance stabilizing angular transformation of the binding percentages was utilized (section 4?1?3; McCullagh, 1983) . Absolute amounts of bound 35 S-labelled PrP C varied, probably as a result of the aggregated state of the PrP Sc isolate used; therefore binding patterns were compared by the analysis of variance method to determine whether significant differences occurred in these binding patterns. Comparisons of binding patterns were made separately for the three PrP C variants and for the two different PrP Sc isolate groups. In order to determine significant differences in binding patterns, the least significant difference (LSD; the minimum amount needed to demonstrate a significant difference) was calculated and compared with the observed differences between the mean binding percentages for either the PrP C variants or the PrP Sc isolate groups.
RESULTS

Binding efficiencies of PrP C to PrP Sc
In total, six independent PrP Sc isolates from six sheep homozygous for 136V-PrP C and six independent PrP Sc isolates from six sheep homozygous for wt-PrP C were isolated and tested for binding affinities to three natural allelic variants of sheep PrP C ; 136V-PrP C (VRQ), wt-PrP C (ARQ) and 171R-PrP C (ARR). At least two independent reaction duplicates were analysed from each PrP Sc isolate. Binding efficiencies of the individual PrP Sc isolates were determined using the conversion-binding assay, in which cell-free conversion conditions used were identical to previous studies, showing significant differential conversion of sheep PrP C variants . Because aggregates were pelleted by spinning for 30 min at 17 500 g, we needed to take into account that not all of the PrP Sc is actually pelleted at this 'low' speed. However, most of the PrP Sc was pelleted (~86?4 % of the total input). Therefore, it can be assumed that the amount of 35 S-labelled PrP C found in the pellet fraction is representative of most if not all of the actual bound 35 S-labelled PrP C . The addition of PrP Sc , isolated from sheep homozygous for 136V-PrP (Fig. 1a) or isolated from sheep homozygous for wt-PrP (Fig. 1b) , resulted in recovering most of the labelled PrP C in the bound pellet (p) fraction ( Fig. 1a and b , lanes 1, 3 and 5) and only a small amount of labelled PrP C remained in the unbound supernatant (s) fraction (Fig. 1a and b, lanes 2, 4 and 6) for each PrP C tested (Table 1; 136V-PrP Sc and wt-PrP Sc isolates). Binding percentages were compared by variance analysis, after variance stabilizing angular transformation of the binding percentages. Firstly, binding patterns were compared between the PrP C variants and no significant differences were found (Fig. 2a) (Fig. 2b) since the LSD between PrP Sc variants was 5?8 %, which is again higher than the maximum difference of 1?1 % between the mean binding percentages for the wt/wt (homozygous wt-PrP) and 136V/136V (homozygous 136V-PrP) PrP Sc isolate groups (86?2±1?7 and 87?3±1?8 %, respectively).
To gain insight into the dynamics of the binding reaction, binding percentages were also determined at shorter incubations (1 h, 1 day, 2 days and the standard 3 days). At each time point, binding percentages were determined of the three PrP C variants to PrP Sc (n=4; two wt/wt and two 136V/136V isolates). No significant differences were found between the three PrP C variants and the overall mean binding percentages at the four time points (Fig. 3) . The boxplot shows the total spread of all determined binding percentages, with the box representing 95 % of all measurements and the line in the box representing the mean value of the measurements. Analysis of variance of the binding percentages shows that neither the PrP C variant nor the PrP Sc isolate group have a significant effect on the binding patterns obtained. (Fig. 4a, lanes 3 and 4) , which is about the same as the amount of PrP C in the pellet fraction of assays without any aggregated protein (see above). To ensure that KLH remained aggregated under the specific conversion conditions used, soluble and pellet fractions were also analysed on SDS-PAGE by total protein staining (Sypro Orange; Molecular Probes). On average 79?8±1?0 % of the added KLH was recovered in the pellet fraction (Fig. 4b, lanes 1 and 2) S-labelled PrP C were detected in the pellet fraction; on average 90?6±2?6 % remained in the supernatant fraction (Fig. 4a, lanes 5 and  6) . To ensure that TG remained largely soluble under the specific conversion conditions used, soluble and pellet fractions were also analysed on SDS-PAGE by total protein staining (Sypro Orange). On average 94?4±2?5 % of the TG remained in the supernatant (Fig. 4b, lanes 3 and 4) (Fig. 4c, lanes 1 and 2) . This indicates that binding of 35 
S-labelled PrP
C by PrP Sc is PrP-specific.
In summary, we have shown that PrP C binds efficiently to PrP Sc with no significant differences in binding patterns between PrP C variants and PrP Sc isolate groups, under conditions maintaining cell-free conversion specificity (Fig. 5) . Furthermore, we have shown that PrP C does not spontaneously aggregate due to the specific conversion condition used, does not stick to unrelated aggregated protein like KLH and does not precipitate with other large soluble proteins like TG. Additionally, we have shown that PrP Sc does not bind to unrelated labelled soluble protein (E2). Therefore, we can conclude that PrP Sc -associated pelleting of 35 Slabelled PrP C represents a PrP C -PrP Sc -specific interaction and that addition of aggregated protein (PrP Sc ) is a prerequisite for pelleting 35 S-labelled PrP C under conditions maintaining cell-free conversion specificity. Since no differences were detected in the binding patterns of the tested PrP C variants to the different PrP Sc isolates, the rate-limiting step determining the observed differential conversion efficiencies of PrP C variants has to be during a subsequent step in the conversion after binding of PrP C to PrP Sc (Fig. 6 ).
DISCUSSION
The aim of this study was to gain insight into the mechanism underlying the modulation of sheep scrapie susceptibility by polymorphisms in PrP C or PrP Sc . Bossers et al. (2000) showed that the in vitro conversion assay is a representative tool for assessing modulating effects of scrapie-associated polymorphisms. Other studies have shown that the conversion of PrP C by PrP Sc is induced by the aggregated forms of PrP Sc (Caughey et al., 1995 . These aggregates can be pelleted by high-speed centrifugation. The amount of 35 S-labelled PrP C that is bound by PrP Sc and subsequently recovered from the pellet should give an indication of whether the disease-associated polymorphisms modulate binding of PrP C by PrP Sc or whether these polymorphisms have their modulating effects in a subsequent step after the initial binding during the conversion.
By applying a conversion-binding assay (Horiuchi et al., 2000) , binding efficiencies of sheep PrP C variants to sheep PrP Sc variants have been measured. Since no significant differences in binding efficiencies were measured between any of the variants, the initial binding efficiencies cannot account for the observed differential conversion efficiencies of sheep scrapie susceptibility-linked variants of PrP. We show for instance that 171R-PrP C binds to PrP Sc as efficiently as 136V-PrP C or wt-PrP C , whereas conversion efficiencies differ remarkably. Therefore, a second (or) further step in the conversion process, in which the disease-associated polymorphisms have their modulating effect, seems to be involved in the conversion of the PrP protein (Fig. 6 ). These findings are corroborated by a study in which interactions between heterologous forms of prion protein have been studied in vitro using mouse and hamster PrP isoforms (Horiuchi et al., 2000) , in which is shown that PrP C of different species (hamster and mouse) bind equally efficiently to PrP Sc of mouse while preserving conversion specificity, also indicating that a second step in the conversion after initial binding should determine the species specificity.
In this study, we also show that S-labelled PrP C under conditions maintaining cell-free conversion specificity. These results are in conjunction with results in which no spontaneous PKresistant PrP was formed under the cell-free conversion conditions when PrP Sc was replaced by SQ water (Bossers et al., 1997 . depend on post-translational modifications or non-specific 'sticky' properties of PrP.
Since 171R-PrP C seems to bind as efficiently to PrP Sc as wt-PrP C and 136V-PrP C , the 171R-PrP C variant may be valuable in firstly, providing clues for designing new therapeutic strategies by determination of the mechanism underlying the refolding process of PrP C into PrP Sc , for example, by using the 171R-PrP C variant to determine sites involved in binding and/or conversion or by comparing protein properties (i.e. stability, unfolding/refolding kinetics). Secondly, since conversion-resistant 171R-PrP C binds efficiently to PrP Sc it may provide a future tool to block prion conversion through direct interference or blocking of PrP Sc polymer growth as hypothesized before by Bossers et al. (1999) . In addition, results from literature show that heterozygosity for PrP is a protective factor against TSE development as demonstrated by studies in vitro (Priola et al., 1994; Holscher et al., 1998; Horiuchi et al., 2000) or in vivo for sheep (Goldmann et al., 1994; Belt et al., 1995; Clouscard et al., 1995; Bossers et al., 1996; Hunter et al., 1996) and humans Palmer et al., 1991) . This is in conjunction with our results showing that various differentially converting PrP C variants bind equally efficiently to PrP Sc but have different conversion efficiencies. In heterozygotes, this 'inhibition' of conversion by heterologous PrP variants might explain why heterozygotes have longer incubation times than their homozygous counterparts. This is corroborated by the fact that resistance in heterozygous sheep is not caused by preferential allelic use (Caplazi et al., 2004) .
The coupled in vitro cell-free conversion efficiencies (Fig. 5 ) reflect results as described before , where susceptibility to scrapie was linked to the modulating effects of polymorphisms on the conversion of sheep PrP. In addition to these in vitro cell-free conversion assays, PrP polymorphisms have been shown to tightly control sheep prion replication in cultured cells (Sabuncu et al., 2003) . Furthermore, it has been shown that polymorphisms in PrP determine both interspecies and intraspecies transmissibilities (Bossers, 1999; Bossers et al., 2003) and/or the stability of the PrP C molecule itself (Rezaei et al., 2002) .
By correlating conversion-and binding-patterns, we showed that 171R-PrP C binds to PrP Sc as efficiently as conversion prone variants like wt (ARQ) and 136V-PrP C . Since naturally occurring polymorphisms of sheep PrP C seem not to have a significant modulating effect on the initial binding of PrP C to PrP Sc , these could somehow modulate a subsequent step in the conversion process (Fig. 6 ). Both 136V and 171R are polymorphisms that affect PrP C stability and are close to the region that supposedly is involved in refolding of PrP C to PrP Sc (Rezaei et al., 2002; Eghiaian et al., 2004) . This region is composed of the two small b-sheets [sheep aa 129-134 (S1) and 163-167 (S2)], which are the positions from where the first a-helix [aa 146-158 (H1)] is converted into an anti-parallel organized b-sheeted structure. It could also be that the 171R polymorphism results in increased protease sensitivity of 171R-PrP C itself due to destabilization of the PrP C molecule (Rezaei et al., 2002) , thus resulting in slower amyloidogenesis because the 171R-PrP C molecule could internalize and be degraded by the PrP-expressing cell more rapidly than the other variants before the actual polymerization can take place. In contrast, the 136V polymorphism could stabilize the PrP C molecule, resulting in an elongation of the survival of 136V-PrP C and thereby supporting the subsequent conversion.
Since disease-associated polymorphisms of sheep PrP do not have an effect on binding properties of PrP C to PrP Sc , dominant-negative inhibition of the 171R polymorphism on prion conversion (Bossers, 1999; Bossers et al., 1999 Bossers et al., , 2000 Perrier et al., 2002 ) is therefore not due to lack of interaction between PrP variants as suggested by Perrier et al. (2002) , but more probably due to a more subtle mode of modulation by the PrP polymorphism on the conversion or on the interaction with chaperone proteins under natural conditions. This study shows that the interaction between PrP C and PrP Sc in the conversion-binding assay is PrP-specific. Whether PrP C binds to the so-called nucleation site of PrP Sc only or whether it can bind to other sites of PrP Sc aggregates is under investigation. The next logical step, currently under investigation, is to find out whether conversion-resistant (natural or artificial) PrP variants can effectively interfere with the process of PrP conversion and thereby therapeutically block or significantly delay TSE development.
